Maternal Marijuana Use and Fetal and Infant Outcome
Status
Conditions
Treatments
Details and patient eligibility
About
Marijuana and cannabis-containing products are growing in popularity and availability in the United States, and use during pregnancy has increased dramatically. The overarching aim of this proposal is to provide pilot data for a submission which will explore the impact of chronic maternal marijuana use (primary or secondary) on fetal functioning, maternal reflective functioning and infant birth and neurodevelopmental outcomes. Chronically marijuana using pregnant women in treatment at the Center for Addiction and Pregnancy will be enrolled and asked to provide information about participants' marijuana and other licit and illicit substance use and feelings about parenting and participants' infant and undergo fetal monitoring at 36 weeks gestation. The neonates will undergo neurobehavioral examination during the first and fourth weeks of life.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Maternal Inclusion Criteria:
- Singleton pregnancy less than 36 weeks of gestation
- Marijuana as a primary or secondary drug of choice
Maternal Exclusion Criteria:
- Significant fetal anomaly
- Multiple gestation
- Delivery prior to 36 weeks gestation
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal